ON
← Back to feed
What happens when you stop taking your GLP-1 medication? Scientists have uncovered disturbing data
Croatia🩺 Health

What happens when you stop taking your GLP-1 medication? Scientists have uncovered disturbing data

A study published in The Lancet Regional Health Europe involving approximately 80,000 patients with type 2 diabetes found that discontinuing GLP-1 receptor agonists was associated with a significantly increased risk of cardiovascular events and death. Specifically, patients who stopped taking the medication faced double the likelihood of heart attacks, strokes, or cardiovascular-related deaths within three to four years compared to those who continued treatment. Overall mortality in the group that discontinued therapy was nearly five times higher, despite similar baseline characteristics between the two groups. Researchers noted that standard risk factors like weight and blood glucose levels did not fully account for this elevated risk, suggesting the drugs provide direct protective benefits beyond metabolic control. Medical experts emphasized that while these findings highlight the importance of continuous treatment for cardiovascular protection, they do not necessarily apply to individuals using the drugs solely for weight loss.

4 reports

N1 Hrvatska logoN1 HrvatskaIndependentCenter
What happens when you stop taking your GLP-1 medication? Scientists have uncovered disturbing data

A study published in The Lancet Regional Health Europe involving approximately 80,000 patients with type 2 diabetes found that discontinuing GLP-1 receptor agonists was associated with a significantly increased risk of cardiovascular events and death. Specifically, patients who stopped taking the medication faced double the likelihood of heart attacks, strokes, or cardiovascular-related deaths within three to four years compared to those who continued treatment. Overall mortality in the group that discontinued therapy was nearly five times higher, despite similar baseline characteristics between the two groups. Researchers noted that standard risk factors like weight and blood glucose levels did not fully account for this elevated risk, suggesting the drugs provide direct protective benefits beyond metabolic control. Medical experts emphasized that while these findings highlight the importance of continuous treatment for cardiovascular protection, they do not necessarily apply to individuals using the drugs solely for weight loss.

Bias read (Center): The article presents medical research findings neutrally, citing specific statistical data and including balanced expert commentary that contextualizes the limitations of the observational study design.

tportal logotportalIndependentCenter
People who stop taking diet pills are at increased risk of death

A study published in The Lancet Regional Health Europe found that patients with type 2 diabetes who stop taking GLP-1 receptor agonists, medications used for weight loss and blood sugar control, face significantly increased risks of serious cardiovascular events and death. The research followed around 80,000 participants, half of whom discontinued their treatment. Those who stopped had twice the risk of heart attack, stroke, or cardiovascular-related death within three to four years, and overall mortality was nearly five times higher compared to those who continued treatment. Researchers emphasized that this does not establish a direct cause-and-effect relationship but highlights the importance of ongoing therapy. Experts noted that while the findings are concerning, they do not confirm that stopping these medications directly causes harm, and more research is needed.

Bias read (Center): The article presents medical research findings objectively, citing multiple experts and emphasizing the limitations of observational studies without overtly favoring any perspective.

Index.hr logoIndex.hrIndependentCenter
Study: Stopping weight-loss therapy in diabetics increases the risk of stroke

A study published in The Lancet Regional Health Europe found that discontinuing GLP-1 receptor agonist therapy increases the risk of cardiovascular events and death among patients with type 2 diabetes. The research involved approximately 80,000 participants who initially started treatment but later stopped taking the medication. Those who discontinued their treatment had double the risk of heart attack, stroke, or death related to cardiovascular disease over the next three to four years. The study highlights that the increased risk cannot be fully explained by factors like weight gain or blood sugar levels. Researchers emphasize that continuous treatment may be necessary to achieve maximum benefits in reducing cardiovascular risks and mortality.

Bias read (Center): The article presents findings from a medical study without overtly favoring any side, using balanced language and citing expert opinions from both the study authors and external experts.

Telegram.hr logoTelegram.hrIndependentCenter
Alarming results from a large study: Stopping weight-loss therapy increases the risk of heart attacks

A large study conducted by researchers in Italy involving approximately 80,000 patients with type 2 diabetes has revealed alarming results regarding the discontinuation of weight-loss therapy. The study found that stopping treatment with GLP-1 receptor agonists significantly increases the risk of serious cardiovascular events, including heart attacks and strokes, as well as mortality. Participants who stopped their medication had double the chance of experiencing such events within three to four years compared to those who continued treatment. Researchers emphasized that this increased risk cannot be fully explained by factors like body weight or blood glucose levels alone. Experts suggest that continuous treatment may be necessary to achieve maximum benefits in reducing cardiovascular risks and mortality.

Bias read (Center): The article presents findings from a scientific study without overtly biased language, balanced presentation of expert opinions, and no clear ideological framing.

How each side covered it

The same event, grouped by the political lean of the outlets covering it.

How each side covered it

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Covered around the world

The same event as reported in other countries.

Covered around the world

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Claims check

Key factual claims, and how many sources assert vs dispute each.

Claims check

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Keep the news honest.

ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €4/month.

Become a Supporter

Related stories